Influence of Mori Folium Polysaccharide of Tangshan on Blood Glucose and Serum Lipoprotein Metabolism in Rats with Experimental Type 2 Diabetes
Tian Chun-y
Abstract
Tian Chun-y
Abstract
Objective:To study the influence of Mori Folium Polysaccharide(MFP)on blood glucose and serum lipoprotein in T2DM rats. Methods:Type 2 diabetes model was induced with high sucrose-fat diet for 4 weeks and STZ by intraperitoneal injection with the dose of 30 mg·kg-1. The rats were randomly divided into groups:model group,MFP low dose(180 mg·kg-1·d-1)and middle dose(360 mg·kg-1·d-1)and high dose treatment group(540 mg·kg-1·d-1),rosiglitazone treatment group(4 mg·kg-1·d-1). Blood glucose,serum lipoprotein,HbAlc and Ins contents in rats were detected after 60 d of continuous medication. Results:FMP can reduce the levels of blood glucose,HbAlc,TG,TCH and LDL and improve the levels of HDL and Ins. Those were significant deviations to compare with those of the model group(P0.05)and it had no significant difference with the rosiglitazone treatment group(P0.05). Conclusion:MFP can effectively reduce the rat's blood glucose of T2DM,promote Ins secretion,correct the disorder of lipid metabolism in diabetic rats and regulate the serum lipoprotein.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective:To study the influence of Mori Folium Polysaccharide(MFP)on blood glucose and serum lipoprotein in T2DM rats. Methods:Type 2 diabetes model was induced with high sucrose-fat diet for 4 weeks and STZ by intraperitoneal injection with the dose of 30 mg·kg-1. The rats were randomly divided into groups:model group,MFP low dose(180 mg·kg-1·d-1)and middle dose(360 mg·kg-1·d-1)and high dose treatment group(540 mg·kg-1·d-1),rosiglitazone treatment group(4 mg·kg-1·d-1). Blood glucose,serum lipoprotein,HbAlc and Ins contents in rats were detected after 60 d of continuous medication. Results:FMP can reduce the levels of blood glucose,HbAlc,TG,TCH and LDL and improve the levels of HDL and Ins. Those were significant deviations to compare with those of the model group(P0.05)and it had no significant difference with the rosiglitazone treatment group(P0.05). Conclusion:MFP can effectively reduce the rat's blood glucose of T2DM,promote Ins secretion,correct the disorder of lipid metabolism in diabetic rats and regulate the serum lipoprotein.
Key concepts: Medicine, Internal medicine, Endocrinology, Rosiglitazone, Diabetes mellitus, Blood lipids, Polysaccharide, Lipoprotein